皮膚がん診断薬・治療薬市場：疾患タイプ別、種類別-2025-2030年の世界予測

皮膚がん診断薬・治療薬市場は、2023年に75億4,000万米ドルと評価され、2024年には83億1,000万米ドルに達すると予測され、CAGR 10.43％で成長し、2030年には151億1,000万米ドルに達すると予測されています。

皮膚がん診断・治療薬市場の範囲は、メラノーマ、基底細胞がん、扁平上皮がんなどの皮膚がんのスクリーニング、診断、治療、管理を含みます。この分野は、皮膚がん罹患率の増加、診断技術の進歩、新規治療薬の開発が原動力となっています。罹患率の上昇と皮膚がんのリスクに対する意識の高まりにより、早期発見と効果的な治療アプリケーションの必要性が最重要視されています。最終用途は主に病院、皮膚科専門クリニック、研究機関であり、患者の転帰を改善するために確立された手法と最先端の手法の両方を活用しています。影響力のある成長要因としては、画像診断や分子診断の技術的進歩、紫外線曝露や高齢化などの要因による皮膚がん患者の増加、研究開発への多額の投資などが挙げられます。新たなビジネスチャンスは、個別化医療のアプローチ、AIを活用した診断ツール、精度と効果の向上を約束する併用療法にあります。投資家や企業は、研究開発協力に注力し、技術系企業との戦略的パートナーシップを拡大することで、こうした動向を活用することをお勧めします。先進的な診断薬の高コスト、規制上のハードル、地域によって異なる償還政策などの限界は、市場進展の課題となっています。さらに、異なる皮膚がんのタイプを正確に診断することの複雑さから、継続的な技術革新と専門知識の開発が求められています。技術革新の可能性のある分野としては、非侵襲的診断技術の開発、免疫療法の改善、リスクのある人の継続的モニタリングのためのウェアラブル・スマートデバイスなどがあります。市場の競争は激しく、急速に進化しており、主要プレーヤーは診断と治療ソリューションの両面でブレークスルーを目指しています。一歩先を行くには、技術の進歩に焦点を当て、規制の変更に積極的に対応し、患者に提供されるケアの質を損なうことなく、利用しやすさと手頃な価格を確保する必要があります。

市場力学：急速に進化する皮膚がん診断薬・治療薬市場の主要市場インサイトを公開

皮膚がん診断薬・治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の皮膚がん罹患率の上昇と認知度の向上
  • 早期発見と皮膚がん治療に対する政府のイニシアチブの高まり
  • 皮膚がん診断薬および治療薬の研究開発パイプラインの急増
• 市場抑制要因
  • 様々な皮膚がん治療に伴う高コスト
• 市場機会
  • 皮膚がん診断薬・治療薬における進歩
  • 新興国における皮膚がん治療の発展
• 市場の課題
  • 皮膚がんに対する放射線治療の副作用

ポーターの5つの力：皮膚がん診断薬・治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：皮膚がん診断薬・治療薬市場における外部からの影響の把握

外部マクロ環境要因は、皮膚がん診断薬・治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析皮膚がん診断薬・治療薬市場における競合情勢の把握

皮膚がん診断薬・治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス皮膚がん診断薬・治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、皮膚がん診断薬・治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で皮膚がんの発生率と認知度が増加
    • 皮膚がんの早期発見と治療に向けた政府の取り組みの強化
    • 皮膚がんの診断と治療の研究開発パイプラインの急増
  • 抑制要因
    • さまざまな皮膚がん治療に伴う高額な費用
  • 機会
    • 皮膚がん診断薬・治療薬の進歩
    • 新興国における皮膚がん治療の発展
  • 課題
    • 皮膚がんに対する放射線治療の副作用
• 市場セグメンテーション分析
  • 疾患の種類：悪性黒色腫の迅速かつ早期の診断と治療の必要性が高まっている
  • タイプ：皮膚がん患者の増加に対応するために皮膚がんの治療法を改善するための進歩
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 皮膚がん診断薬・治療薬市場：疾患タイプ別

• 悪性黒色腫
• 非黒色腫

第7章 皮膚がん診断薬・治療薬市場：タイプ別

• 診断
  • 血液検査
  • 皮膚鏡検査
  • 画像検査
  • リンパ節生検
  • 皮膚生検
• 治療薬
  • 化学療法
  • 非侵襲的治療
  • 手術

第8章 南北アメリカの皮膚がん診断薬・治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の皮膚がん診断薬・治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの皮膚がん診断薬・治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDA、初のAI搭載皮膚がん診断ツールを承認
  • サンファーマとフィロジェンが協力し、欧州で皮膚がん治療薬を商品化
  • 洞察、転移性/再発性局所進行性メルケル細胞がん（MCC）の治療としてZynyz（レティファンリマブ-Dlwr）のFDA承認を発表

企業一覧

• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Agilent Technologies, Inc.
• Elekta AB
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• DermTech, Inc. by Bausch Health Companies Inc.
• Castle Biosciences, Inc.
• Veriskin Inc.
• NeraCare GmbH
• AB Science
• Eli Lilly and Company
• GlaxoSmithKline PLC
• bioMerieux SA
• Sirnaomics, Inc.
• Merck & Co., Inc.
• AstraZeneca PLC
• SkylineDx BV
• Pfizer Inc.
• DAMAE Medical
• Novartis AG
• Amgen, Inc.
• QIAGEN N.V.
• Sun Pharmaceutical Industries Ltd.
• AMLo Biosciences Ltd.
• Almirall, S.A.
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 61. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 65. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 134. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 150. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 154. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 191. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Skin Cancer Diagnostics & Therapeutics Market was valued at USD 7.54 billion in 2023, expected to reach USD 8.31 billion in 2024, and is projected to grow at a CAGR of 10.43%, to USD 15.11 billion by 2030.

The scope of the skin cancer diagnostics and therapeutics market encompasses the screening, diagnosis, treatment, and management of skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. This field is driven by increasing skin cancer prevalence, advances in diagnostic technologies, and the development of novel therapeutics. The necessity for early detection and effective treatment applications is paramount due to rising incidences and growing awareness about skin cancer risks. End-use is primarily within hospitals, specialized dermatology clinics, and research institutions, leveraging both established and cutting-edge methodologies to improve patient outcomes. Influential growth factors include technological advancements in imaging and molecular diagnostics, the increase in skin cancer cases due to factors like UV exposure and aging populations, and significant investments in research and development. New opportunities lie in personalized medicine approaches, AI-powered diagnostic tools, and combination therapies that promise better precision and effectiveness. Investors and companies are advised to capitalize on these trends by focusing on R&D collaborations and expanding strategic partnerships with technological firms. Limitations such as high costs of advanced diagnostics, regulatory hurdles, and varying reimbursement policies across regions pose challenges for market progression. Furthermore, the complexity of accurately diagnosing different skin cancer types demands continuous innovation and expertise development. Potential areas for innovation include the development of non-invasive diagnostic techniques, improved immunotherapies, and wearable smart devices for continuous monitoring of at-risk individuals. The nature of the market is competitive and rapidly evolving, with key players striving for breakthroughs in both diagnostics and treatment solutions. Staying ahead requires a focus on technological advancements and proactive adaptation to regulatory changes, ensuring accessibility and affordability without compromising on the quality of care offered to patients.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Skin Cancer Diagnostics & Therapeutics Market

The Skin Cancer Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing Incidences and Rising Awareness of Skin Cancer Globally
  • Rising Government Initiatives for Early Detection and Skin Cancer Treatment
  • Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
• Market Restraints
  • High Cost Associated With the Various Skin Cancer Treatment
• Market Opportunities
  • Advancements in Skin Cancer Diagnostics & Therapeutics
  • Developments of Skin Cancer Care in Emerging Nations
• Market Challenges
  • Side Effects of Radiation Therapy for Skin Cancer

Porter's Five Forces: A Strategic Tool for Navigating the Skin Cancer Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Skin Cancer Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Skin Cancer Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Skin Cancer Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Skin Cancer Diagnostics & Therapeutics Market

A detailed market share analysis in the Skin Cancer Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Skin Cancer Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Skin Cancer Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Skin Cancer Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include F. Hoffmann-La Roche AG, Abbott Laboratories, Agilent Technologies, Inc., Elekta AB, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, DermTech, Inc. by Bausch Health Companies Inc., Castle Biosciences, Inc., Veriskin Inc., NeraCare GmbH, AB Science, Eli Lilly and Company, GlaxoSmithKline PLC, bioMerieux SA, Sirnaomics, Inc., Merck & Co., Inc., AstraZeneca PLC, SkylineDx BV, Pfizer Inc., DAMAE Medical, Novartis AG, Amgen, Inc., QIAGEN N.V., Sun Pharmaceutical Industries Ltd., AMLo Biosciences Ltd., Almirall, S.A., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Skin Cancer Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Melanoma and Non-melanoma.
• Based on Type, market is studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy. The Therapeutics is further studied across Chemotherapy, Non-invasive Therapy, and Surgery.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing Incidences and Rising Awareness of Skin Cancer Globally
    • 5.1.1.2. Rising Government Initiatives for Early Detection and Skin Cancer Treatment
    • 5.1.1.3. Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost Associated With the Various Skin Cancer Treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Skin Cancer Diagnostics & Therapeutics
    • 5.1.3.2. Developments of Skin Cancer Care in Emerging Nations
  • 5.1.4. Challenges
    • 5.1.4.1. Side Effects of Radiation Therapy for Skin Cancer
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas
  • 5.2.2. Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

• 6.1. Introduction
• 6.2. Melanoma
• 6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Type

• 7.1. Introduction
• 7.2. Diagnosis
  • 7.2.1. Blood Tests
  • 7.2.2. Dermatoscopy
  • 7.2.3. Imaging Tests
  • 7.2.4. Lymph Node Biopsy
  • 7.2.5. Skin Biopsy
• 7.3. Therapeutics
  • 7.3.1. Chemotherapy
  • 7.3.2. Non-invasive Therapy
  • 7.3.3. Surgery

8. Americas Skin Cancer Diagnostics & Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
  • 11.3.2. Sun Pharma, Philogen Collaborate to Commercialise Skin Cancer Drug in Europe
  • 11.3.3. Incyte Announces FDA Approval Of Zynyz (Retifanlimab-Dlwr) For Treatment Of Metastatic/Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

Companies Mentioned

• 1. F. Hoffmann-La Roche AG
• 2. Abbott Laboratories
• 3. Agilent Technologies, Inc.
• 4. Elekta AB
• 5. Bristol-Myers Squibb Company
• 6. Daiichi Sankyo Company, Limited
• 7. DermTech, Inc. by Bausch Health Companies Inc.
• 8. Castle Biosciences, Inc.
• 9. Veriskin Inc.
• 10. NeraCare GmbH
• 11. AB Science
• 12. Eli Lilly and Company
• 13. GlaxoSmithKline PLC
• 14. bioMerieux SA
• 15. Sirnaomics, Inc.
• 16. Merck & Co., Inc.
• 17. AstraZeneca PLC
• 18. SkylineDx BV
• 19. Pfizer Inc.
• 20. DAMAE Medical
• 21. Novartis AG
• 22. Amgen, Inc.
• 23. QIAGEN N.V.
• 24. Sun Pharmaceutical Industries Ltd.
• 25. AMLo Biosciences Ltd.
• 26. Almirall, S.A.
• 27. Sanofi S.A.